v3.25.1
Note 8 - Segment Reporting - Reconciliation of Net Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Total revenues $ 0 $ 0
Adjusted general and administrative 7,731 3,874
Total other income, net 1,249 478
Net loss (16,795) (10,137)
Operating Segments [Member]    
Total revenues 0 0
Cross platform research and engineering [1] 3,465 3,212
Manufacturing [2] 1,636 1,022
Clinical and regulatory [3] 1,530 702
Adjusted general and administrative [4] 3,791 3,332
Sales and marketing [5] 1,659 289
Other segment items [6] 5,963 2,058
Total other income, net (1,249) (478)
Net loss $ (16,795) $ (10,137)
[1] Cross platform research and engineering includes compensation costs, fees paid to consultants and outside service providers and organizations, prototype spending and other expenses relating to the acquisition, design and development of the Company’s clinical stage devices.
[2] Manufacturing includes compensation costs, fees paid to consultants and outside service providers and organizations, and costs associated with the procurement of materials and the manufacturing of the Company’s clinical stage devices.
[3] Clinical and regulatory includes compensation costs, fees paid to consultants and outside service providers and organizations, and costs associated with clinical trials and regulatory approvals required for the development of the Company’s clinical stage devices.
[4] Adjusted general and administrative includes compensation costs and fees paid to consultants and outside service providers and organizations in support of the administrative functions of the Company, including finance, legal and human resources.
[5] Sales and marketing includes compensation costs, fees paid to consultants and outside service providers and organizations, costs associated with marketing and sales strategy as well as execution of marketing and sales initiatives for the Company's products.
[6] Other segment items includes stock-based compensation, depreciation and amortization, and facilities and IT costs allocations.